Foresee Pharmaceuticals Co., Ltd. (6576.TWO)
Taipei Exchange · TWD · Healthcare · Drug Manufacturers - Specialty & Generic
NT$75.70 (+0.66%) as of
Key statistics
- Market cap
- 11.93B
- P/E (TTM)
- 540.71
- Forward P/E
- -26.38
- EPS (TTM)
- 0.14
- Dividend yield
- 0.00%
- 52-week range
- 71.90 – 93.70
- Beta
- 0.57
- Revenue (TTM)
- 471.13M
- Profit margin
- 4.77%
- Analyst target
- NT$153.00
- Volume
- 2.31k
About Foresee Pharmaceuticals Co., Ltd.
Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline products consist of FP-020 to treat sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients; and FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia, as well as FP-040, an ALDH2 activator to treat central nervous system diseases. The company was incorporated in 2013 and is headquartered in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Taipei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.